Physician profile
Imad Salahuddin
NPI 1366704926
$2,710.24
in general payments reported to CMS, 2019-2025
19 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $127 · 2021: $316 · 2022: $425 · 2023: $764 · 2024: $240 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $454.75 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $265.69 | 2019-2024 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.64 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $241.61 | 2019-2022 | |
| Pfizer INC. | $213.08 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.81 | 2019-2024 | Jardiance |
| Csl Behring | $157.28 | 2019-2025 | Kcentra |
| Alexion Pharmaceuticals, INC. | $115.00 | 2022-2023 | Ultomiris |
| Vifor Pharma, INC. | $109.21 | 2019-2023 | Veltassa |
| Merck Sharp & Dohme LLC | $104.18 | 2019-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $101.65 | 2019-2023 | |
| Astellas Pharma US INC | $94.86 | 2019-2022 | |
| Shionogi INC | $89.97 | 2022-2024 | Fetroja |
| Ferring Pharmaceuticals INC. | $81.52 | 2023-2025 | Rebyota |
| Insmed, INC. | $78.79 | 2023 | Arikayce |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $62.67 | 2025 | |
| Paratek Pharmaceuticals, INC. | $53.66 | 2019-2024 | Nuzyra |
| Aimmune Therapeutics, INC. | $23.83 | 2025 | Vowst |
| Bayer Healthcare Pharmaceuticals INC. | $23.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Salahuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.